Walgreens Boots Alliance — Q3 2021 Earnings Presentation
35 slides from Walgreens Boots Alliance's earnings presentation, Jul 1, 2021
Slide 1: Fiscal 2021 Third Quarter Results
Fiscal 2021 Third Quarter Results July 1, 2021 © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 1
Slide 2: Safe harbor and non-GAAP
Safe harbor and non-GAAP Cautionary Note Regarding Forward-Looking Statements: All statements in these materials and the related presentation that are not historical including, without limitation, estimates of and goals for future operating, financial and tax performance and results, including our f
Slide 3: Introduction
Introduction • Delivered a very strong quarter • Alliance Healthcare divestiture is complete • Strong execution in the administration of COVID-19 vaccines in the U.S. • Continued investments to innovate for the future © 2021 Walgreens Boots Alliance, Inc. All rights reserved. Refer to safe harbor an
Slide 4: Playing a key role in pandemic recovery
Playing a key role in pandemic recovery >25m vaccinations administered to date 95% of Walgreens locations administering vaccines Vaccinations >1,100 off-site clinics in medically underserved communities >9m tests since pandemic onset Trained pharmacy staff; expanded testing capabilities to ~6k locat
Slide 5: WBA Financial Performance
WBA Financial Performance © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 5
Slide 6: 3Q financial highlights
3Q financial highlights • Total adjusted EPS $1.51; exceeded expectations ⎯ +81.4% above prior year in constant Fx • Continuing operations adjusted EPS $1.38 ⎯ +93.6% above prior year in constant Fx ⎯ Includes benefit from COVID-19 • Strong cash generation year-to-date ⎯ Operating cash flow $4.3bn ⎯
Slide 7: 3Q financial highlights
3Q financial highlights Results Reported Fx Constant Fx 3Q21 $ in millions (except EPS) B/(W) vs. 3Q20 B/(W) vs. 3Q20 Sales (continuing) $34,030 + 12.1% + 10.4% Operating income GAAP $1,134 + $2,817 (continuing) Adjusted $1,459 + 82.9% + 82.4% EPS - total GAAP $1.38 + $3.33 Adjusted $1.51 + 83.4% +
Slide 8: Year-to-date FY21 financial highlights
Year-to-date FY21 financial highlights Results Reported Fx Constant Fx YTD21 $ in millions (except EPS) B/(W) vs. YTD20 B/(W) vs. YTD20 Sales (continuing) $98,247 + 7.2% + 6.1% Operating income GAAP $1,432 + $1,058 (continuing) Adjusted $3,881 + 4.2% + 3.9% EPS - total GAAP $2.21 + $2.12 Adjusted $4
Slide 9: United States – financials
United States – financials Continuing operations $ in millions 3Q21 B/(W) vs. 3Q20 YTD21 B/(W) vs. YTD20 Sales $28,743 + 5.1% $83,250 + 3.1% Adj. gross profit $6,149 + 14.5% $17,525 + 2.9% Adj. SG&A % of sales 16.8% - 0.2%p 17.0% 0.0%p Adj. operating income $1,471 + 50.3% $3,789 + 2.3% Adj. operatin
Slide 10: United States – pharmacy
United States – pharmacy 3Q 3Q YTD YTD 3Q21 vs. 3Q20 Total Comparable Total Comparable Pharmacy sales + 6.3% + 8.4% + 5.1% + 6.0% Prescriptions + 8.7% + 9.8% + 2.3% + 3.8% • 3Q Rx script comp. grew +9.8% boosted by COVID-19 immunizations ~+6% ⎯ COVID-19 vaccinations 17 million in the quarter • Pharm
Slide 11: United States – retail
United States – retail 3Q YTD 3Q21 vs. 3Q20 Total retail sales + 1.4% - 2.6% Comparable retail sales + 1.7% - 0.5% • 3Q comp. retail sales +1.7%; excluding tobacco & e-cig. +2.6%, improving sequentially ⎯ Weak cough, cold and flu ebbs and mass personalization boosts results ⎯ Store traffic accelerat
Slide 12: International – financials
International – financials Continuing operations Constant Fx Constant Fx $ in millions 3Q21 B/(W) vs. 3Q20 YTD21 B/(W) vs. YTD20 Sales $5,288 + 58.7% $14,998 + 28.3% Adj. gross profit $1,060 + 38.6% $3,129 + 0.0% Adj. SG&A % of sales 18.3% + 9.2%p 18.7% + 6.7%p Adj. operating income $94 + $222 $326
Slide 13: Boots UK – financials
Boots UK – financials 3Q YTD 3Q21 vs. 3Q20 (constant Fx) Pharmacy comp. sales + 3.7% + 3.1% Retail comp. sales + 38.7% - 3.2% • Pharmacy comp. sales +3.7%; demand for additional services and favorable NHS funding phasing more than offset lower prescription volume • Phased reopening of UK high street
Slide 14: Cash flow
Cash flow B/(W) $ in millions YTD21 vs. YTD20 Operating cash flow $4,310 $912 Cash capital expenditure $1,001 ($39) Free cash flow $3,309 $873 • Strong free cash flow generation up +36% vs. prior year ₋ Reflects strong operating profit performance and continued focus on working capital, led by payme
Slide 15: Fiscal year 2021 guidance
Fiscal year 2021 guidance • Completed the divestiture of Alliance Healthcare • Maintaining TCMP goal of delivering in excess of $2bn in annual cost savings by FY22 • 3Q especially strong ⎯ Year-ago quarter exceptionally weak due to the peak of pandemic and “stay-at-home” restrictions ⎯ Retail recove
Slide 16: Fiscal year 2021 guidance
Fiscal year 2021 guidance Constant currency continuing operations adj. EPS growth: ~10% • Raising guidance from mid-to-high single digit to ~10% adj. EPS growth • Key swing factors: ₋ Vaccinations: now expecting 28 million driven by strong execution ₋ COVID-19 recovery and lapping prior year PPE ₋ I
Slide 17: Strategic Initiatives
Strategic Initiatives © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 17
Slide 18: U.S. Pharmacy initiatives
U.S. Pharmacy initiatives • Redefining operations with iA Rx automation ⎯ Automated micro-fulfillment centers operating in Phoenix & Dallas will soon ramp to serve ~1,000 locations ⎯ Best in class efficiency while unlocking the pharmacist time ⎯ Next nine markets identified for deployment by end of
Slide 19: U.S. Retail initiatives
U.S. Retail initiatives • Customer Engagement Platform learnings enhancing personalized offerings ⎯ myWalgreens membership +34% vs. prior quarter to ~75m members to date ⎯ Mass personalization boosted 3Q retail sales comps by ~100bps • Omni-channel offerings resonating & building momentum ⎯ Curbside
Slide 20: International initiatives
International initiatives • Launching innovative digital healthcare services ⎯ Boots Health Hub providing a marketplace for Boots and third-party online healthcare services ⎯ Boots ONLINE DOCTOR launched; delivering a market leading proposition for >40 conditions with more to come • Strong market sh
Slide 21: © 2021 Walgreens Boots Alliance, Inc. All rights reserved. © 2020 Walgreens Boots Alliance,
© 2020 Walgreens Boots Alliance, Inc. All rights reserved. © 2021 Walgreens Boots Alliance, Inc. All rights reserved. Refer to safe harbor and non-GAAP on page 2 and endnotes on page 22 Confidential and Proprietary information. For internal use only. 21
Slide 22: Endnotes
Endnotes • Unless otherwise noted, all prior year numbers have been recast for continuing operations. Refer to WBA's Current Report on Form 8-K filed on March 31, 2021. • Please see appendix for reconciliations of non-GAAP financial measures and related disclosures ◦ The company presents certain inf
Slide 23: Appendix
Appendix The information on the following pages provides reconciliations of the supplemental non-GAAP financial measures, as defined under SEC rules, presented in this presentation and discussed on the related conference call to the most directly comparable financial measures calculated and presente
Slide 24: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended May 31, Change vs. 3Q20 Nine months ended May 31, Change vs. FY20 2021 2020 Amount Percent 2021 2020 Amount Percent Net Ear
Slide 25: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended May 31, Change vs. 3Q20 Nine months ended May 31, Change vs. FY20 2021 2020 Amount Percent 2021 2020 Amount Percent Adjustm
Slide 26: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended May 31, Change vs. 3Q20 Nine months ended May 31, Change vs. FY20 2021 2020 Amount Percent 2021 2020 Amount Percent Net ear
Slide 27: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) DILUTED NET EARNINGS (LOSS) PER SHARE Three months ended May 31, Change vs. 3Q20 Nine months ended May 31, Change vs. FY20 2021 2020 Amount Percent 2021 2020 Amount Perc
Slide 28: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Adjustments to equity earnings (loss) in AmerisourceBergen consist of the Company’s proportionate share of non-GAAP adjustments reported by AmerisourceBergen consisten
Slide 29: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended May 31, 2021 Walgreens Boots United States1 International Corporate and Other Alliance, Inc. Sales $ 28,743 $ 5,288 $ — $ 34,030 Gross p
Slide 30: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) Three months ended May 31, 2020 (in millions) Walgreens Boots United States1 International Corporate and Other Alliance, Inc. Sales $ 27,357 $ 3,008 $ — $ 30,364 Gross p
Slide 31: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Nine months ended May 31, 2021 Supplemental Information (unaudited) Walgreens Boots (in millions) United States1 International Corporate and Other Alliance, Inc. Sales $ 83,250 $ 14,998 $ — $ 98,247 Gross p
Slide 32: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) Nine months ended May 31, 2020 (in millions) Walgreens Boots United States1 International Corporate and Other Alliance, Inc. Sales $ 80,734 $ 10,878 $ — $ 91,612 Gross p
Slide 33: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) EQUITY EARNINGS (LOSS) IN AMERISOURCEBERGEN Three months ended May 31, Nine months ended May 31, 2021 2020 2021 2020 Equity earnings in AmerisourceBergen (
Slide 34: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) ADJUSTED EFFECTIVE TAX RATE Three months ended May 31, 2021 Three months ended May 31, 2020 Earnings before Earnings before income tax Income tax Effective
Slide 35: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) FREE CASH FLOW Three months ended May 31, Nine months ended May 31, 2021 2020 2021 2020 Net cash provided by operating activities (GAAP) 1 $ 1,754 $ 914 $
Walgreens Boots Alliance — Q3 2021 Earnings Presentation on 6ix